Background The effect of sacubitril-valsartan in heart failure patients with mid-range
(HFmEF) and preserved (HFpEF) ejection fractions remains unclear. This study aimed to …

Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range
ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of …

Background Controversy has persisted over the clinical benefits of low‐dose
sacubitril/valsartan in patients with heart failure (HF). Hypothesis Low‐dose …

Aims ARIADNE aimed to assess the association between effects of sacubitril/valsartan and
no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and
cardiovascular mortality in a randomized controlled trial. However, little is known about real …

Aims To compare baseline characteristics of patients with heart failure with reduced ejection
fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on …

We conducted a systematic review and meta-analysis to assess all-cause mortality and
heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF …